FR0012127173
© Globe Newswire
17.11.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
News Preview
OSE Immunotherapeutics annonce que le Comité indépendant d’experts scientifiques (IDMC) recommande la poursuite d’ARTEMIA, l’essai pivot de Phase 3 de Tedo...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
News Preview
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel
“Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions
composant le capital...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
30.10.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions
composant le capital...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
15.10.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reports First Half 2025 Financial Results
News Preview
OSE Immunotherapeutics Reports First Half 2025 Financial Results...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
OSE
LISTED
EURONEXT
Appointment of Marc Le Bozec as Interim CEO
News Preview
Appointment of Marc Le Bozec as Interim CEO...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
OSE
LISTED
EURONEXT
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
News Preview
Full renewal of the Board of DirectorsElection of Dr. Markus Cappel as Chairman of the Board of Directors...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
News Preview
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025
News Preview
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
OSE
LISTED
EURONEXT
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
News Preview
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share CapitalClarification in Response to Unfounded Accusations...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
News Preview
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
OSE
LISTED
EURONEXT
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
News Preview
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
12.09.2025
OSE
LISTED
EURONEXT
Update on Information Relating to the General Meeting of September 30, 2025
News Preview
Update on Information Relating to the General Meeting of September 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
News Preview
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025
News Preview
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance Publication of Circular for Combined Annual General Meeting of September 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025
News Preview
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
News Preview
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
News Preview
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
News Preview
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
News Preview
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General MeetingNew Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi® and Lusvertikimab...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.08.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
News Preview
OSE Immunotherapeutics Launches Newsletter for Individual Shareholders...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2025
OSE
LISTED
EURONEXT
Half-Year Report on Liquidity Contract with Invest Securities
News Preview
Half-Year Report on Liquidity Contract with Invest Securities...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
News Preview
OSE Immunotherapeutics provides an update on ongoing proceedings...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Publishes Letter to Shareholders
News Preview
OSE Immunotherapeutics Publishes Letter to Shareholders...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics provides an update on ongoing proceedings
News Preview
OSE Immunotherapeutics provides an update on ongoing proceedings...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
News Preview
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2025
OSE
LISTED
EURONEXT
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
News Preview
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.06.2025
OSE
LISTED
EURONEXT
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
News Preview
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.06.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
News Preview
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
OSE
LISTED
EURONEXT
Ose Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025
News Preview
Documents made available to the shareholders for the combined general meeting of June 25th, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
News Preview
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies
News Preview
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
News Preview
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
OSE
LISTED
EURONEXT
Mise à disposition du Document d’Enregistrement Universel incluant le Rapport Financier 2024
News Preview
Mise à disposition du Document d’Enregistrement Universel incluant le Rapport Financier 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.04.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
News Preview
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
News Preview
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
News Preview
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.03.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer
News Preview
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.03.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.03.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
News Preview
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
News Preview
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
News Preview
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic ColitisIn Oral Presentation at 20th Congress of ECCO...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.02.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy
News Preview
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
News Preview
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
OSE
LISTED
EURONEXT
Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.12.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO
News Preview
A clinical abstract on the induction results from the CoTikiS Phase 2 trial of anti-IL-7 Receptor Lusvertikimab in Ulcerative Colitis accepted for Oral Presentation and selected amongst the Top 10 oral abstracts for 20th Congress of European Crohn’s and Colitis Organization (ECCO) Highlights....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital
News Preview
Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Strengthens Leadership and Executive Committee
News Preview
OSE Immunotherapeutics Strengthens Leadership and Executive Committee...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Nantes, le 4 novembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), société intégrée de biotechnologie qui développe des immunothérapies innovantes, en direct ou via des partenariats, pour l’activation et la régulat...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
News Preview
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
News Preview
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking1 cytokine technology in oral presentations selected for international conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2024
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
al...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
News Preview
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
